Pharmaceutical companies are focusing on patient and site centric features.

Cost savings- ability to reduce study drop-out rates;

save time and money for sites, patients and sponsors.

R

Virtual visits/platform improve protocol compliance and study retention.

R

Increase geographic reach and diversity of patient populations.

R

BYOD model- app works on any device; no provisioning of devices.

R

Video, audio, messaging interpretation available (183 languages)

SCRS Global Impact Partner

Site members have access/training to become virtually certified.
Pharma can continue to use their preferred site networks

  • Real-time reporting of AEs/ more accurate data
  • Hybrid model assures continued PI oversight
R

Retention and engagement features can be built at study level.

R

Provides innovation and disrupts a portion of the broken drug development process.

R

Designed from site and patient perspective; industry veterans.